<DOC>
	<DOCNO>NCT01244906</DOCNO>
	<brief_summary>This trial evaluate safety efficacy post-transplant Cy sirolimus follow reduce intensity allogeneic SCT . It hop combination reduce intensity preparative regimen calcineurin-free GVHD prophylaxis regimen decrease risk acute chronic GVHD , limit mucosal toxicity augment immune reconstitution , thereby improve safety procedure . The past experience post-transplant Cy suggest SCT recipient attain rapid donor T cell chimerism , investigator hope translate improved disease control well document graft-versus-malignancy effect donor T cell .</brief_summary>
	<brief_title>Post-transplant Cyclophosphamide Sirolimus Following Reduced Intensity Conditioning ( RIC ) Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Availability 7/8 8/8 ( HLAA , B , C , DR ) relate unrelated donor Age 1875 One follow highrisk malignancy Chronic Myelogenous Leukemia Acute Myelogenous Leukemia Myelodysplastic Syndrome Myelofibrosis Acute Lymphocytic Leukemia Acute Lymphoblastic Lymphoma Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Lowgrade nonHodgkin 's Lymphoma Mantle Cell Lymphoma Hodgkin Lymphoma Myeloma Poor cardiac function ( EF &lt; 40 % ) Poor pulmonary function ( FEV1 FVC &lt; 50 % predict ) Poor liver function ( bilirubin &gt; /= 2 mg/dl due hemolysis , Gilbert 's primary malignancy ) Poor renal function ( creatinine &gt; /= 2 mg/dl creatinine clearance &lt; 40mL/min ) Karnofsky status &lt; 70 % HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Acute Lymphoblastic Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>Low-grade non-Hodgkin 's Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Myeloma</keyword>
</DOC>